Vext Science (VEXT) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $11.6 million, up 38% year-over-year and 13% sequentially, driven by strong adult-use sales in Ohio and resilience in Arizona despite market headwinds.

• Operating cash flow was $3.1 million, nearly matching all of 2024, with a cash flow margin improving to 27%.

• The company’s retail-first strategy, capital efficiency, and operational discipline are credited for the strong performance.

• Closed acquisition of two Ohio dispensaries post-quarter, doubling the Ohio retail footprint to four locations, with a fifth under construction.

Financial highlights

• Adjusted EBITDA for Q1 2025 was $3.4 million, with a 29% margin, among the highest for U.S. public multi-state cannabis operators.

• Net income after taxes was a loss of $3.33 million in Q1 2025.

• Operating expenses remained flat year-over-year, declining as a percentage of revenue from 54% to 38%.

• Ended the quarter with $4.8 million in cash and no anticipated need for capital raises.

• Cash flow margin improved to 27% in Q1 2025 from 1% in Q1 2024.

Outlook and guidance

• Ohio is expected to remain a key growth engine, with retail as the dominant revenue driver by 2026.

• Additional Ohio dispensaries will be consolidated in Q2, expected to boost top-line and margin performance.

• Focus remains on generating free cash flow, paying down debt, and expanding the Ohio retail footprint.

• Retail-first strategy and capital-light build-out model expected to drive further growth in 2025.

• No significant capex or acquisition payments remain for new Ohio stores; 30% of the $4 million expansion capex has been spent.